Results 51 to 60 of about 5,822 (192)
Dry eye syndrome in thyroid-associated ophthalmopathy
Purpose: The pathogenesis of keratoconjunctivitis sicca in patients with thyroid eye disease is presented. The influence of therapy by a HYLO-PARIN® on a condition of a tear film in patients with various forms of thyroid eye disease is assessed. Methods:
A. F. Brovkina +2 more
doaj +3 more sources
The diagnostic model combining orbital and intracranial MAP‐MRI parameters could significantly optimize diagnostic efficiency of dysthyroid optic neuropathy. Comprehensive MAP‐MRI parameters analysis of the entire visual pathway enables a deeper understanding of disease involvement, provides novel insights into the early accurate diagnosis and ...
Mengsha Zou +7 more
wiley +1 more source
Ocular myasthenia gravis (Ocular MG, OMG) shares many clinical features with thyroid-associated orbitopathy or thyroid-associated ophthalmopathy (TAO). In the rare instance of their coexistence, clinicians may fail to diagnose ocular MG when TAO is also ...
Ran An +5 more
doaj +1 more source
Chronic Progressive External Ophthalmoplegia Masquerading as Thyroid Associated Ophthalmopathy [PDF]
Chronic progressive external ophthalmoplegia (CPEO) is marked by progressive bilateral ptosis and reduction in ocular motility without other systemic symptoms of mitochondrial dysfunction.1 Conversely thyroid-associated ophthalmopathy (TAO) may present ...
Nina S. Boal; Alberto Distefano; Anna Kupcha
core
Microbiome in orbital fat under thyroid associated ophthalmopathy
Thyroid associated ophthalmopathy (TAO) manifests as orbital adipose hyperplasia, leading to high intraocular pressure, severe pain, and blindness. The underlying factors that trigger the abnormal immune process in TAO remain unknown.
Yang Li +6 more
doaj +1 more source
Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar +5 more
wiley +1 more source
Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset +13 more
wiley +1 more source
TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang +16 more
wiley +1 more source
Unilateral Thyroid Associated Ophthalmopathy [PDF]
At present, no laboratory test or clinical finding pathognomic for Thyroid Associated Ophthalmopathy (TAO) are currently recognized. The recognized clinical diagnostic criteria for TAO are: eyelid retraction or not, exophthalmos, optic nerve dysfunction,
Antonella Boschi, MD; S. Bianchi-Marzoli, MD; C. Kolanowski, MD; C. Sannace, MD; R. Brancato, MD; M. C. Manie, MD; C. Daumerie, MD
core
Study of Deiodinase Type 2 Polymorphisms in Graves' Disease and Ophthalmopathy in a Swedish Population [PDF]
Background: Deiodinase type 2 (DIO2) is an enzyme that catalyzes the production of the active form of thyroid -hormone triiodothyronine (T3) from thyroxine (T4) and is important for maintaining intracellular T3 levels.
Åsman, Peter, +4 more
core +1 more source

